TABLE OF CONTENTS

Volume 21, Issue 2

ACNR is a UK-based, international, open access, peer reviewed neurology journal which aims to keep busy practicing specialists up-to-date with the latest advances in their fields.

ISSN 1473-9348


Clinical Review Articles
  • Confidence College – an online education tool for neurology patients
  • Heather Angus-Leppan, Alice Caulfield, Melika M Moghim, Jennifer Nightingale, Rob Sloan, Tom Stables, Michael Oates, Bernadette Porter, Anette Schrag
Movement Disorders
  • Physical activity and exercise for people with Parkinson’s
  • Julie Jones, Katherine Baker, Bhanu Ramaswamy
Epilepsy Series
  • The Comorbidities of Epilepsy: Introduction
  • Marco Mula
  • Seizures and sleep: Not such strange bedfellows
  • Guy Leschziner
Sleep Series
  • Psychostimulants as cognitive enhancers – the evidence for the use and abuse of smart drugs
  • Poppy Goldsmith and Kirstie Anderson
Headache Series
  • Vestibular migraine
  • Nitesh Patel, Kulvinder Talewar, Anish Bahra, Diego Kaski
Special Features
  • Rehabilitating Romberg
  • Mark R Baker, Timothy L Williams, Andrew Larner
  • Arnold’s Nerve
  • JMS Pearce

Related

  • HOME
  • ISSUES
  • EXPLORE CONTENT
    • Introduction
    • Articles
    • Book Reviews
    • Case Reports
    • News
    • Sponsored Editorial
  • EVENTS
    • Introduction
    • Event News
    • Conference Reports
    • Submit your event to ACNR
  • AUTHORS
    • Introduction
    • Author Guidelines
    • Author Disclosure
  • RESOURCES
  • ABOUT
    • Introduction
    • How is ACNR funded?
    • Editorial Board
    • Peer Reviewers
    • Policies and Forms
    • Ethics and Malpractice
    • Email Newsletter
    • Mail Signup
    • ACNR Privacy Policy
This website is intended for healthcare professionals
ACNR
  • HOME
  • ISSUES
  • EXPLORE CONTENT
    • Introduction
    • Articles
    • Book Reviews
    • Case Reports
    • News
    • Sponsored Editorial
  • EVENTS
    • Introduction
    • Event News
    • Conference Reports
    • Submit your Event to ACNR
  • AUTHORS
    • Introduction
    • Author Guidelines
    • Author Disclosure
  • RESOURCES
  • ABOUT
    • Introduction
    • How is ACNR Funded?
    • Editorial Board
    • Peer Reviewers
    • Policies and Forms
    • Ethics and Malpractice
    • Email Newsletter
    • Mail Signup
    • ACNR Privacy Policy
  • Menu

ACNR ARTICLES

Nutrition and Stem Cells series: introduction

Author

  • Rosemary Fricker
  • PhD HFEA
  • Professor of Neurobiology at Keele University

Editor of ACNR's Nutrition and Stem Cells series. She is visiting Professor of Neurobiology at Keele University, and formerly Director of Medical Science, at Keele Medical School.

  • Correspondence Email:
  • r.a.fricker@keele.ac.uk

Publication Dates:

Publication Date:
04 Nov 2020


Article Categories

  • ABN (5)
  • ABNT (7)
  • Alzheimer's Disease (3)
  • Australia/NewZealand (32)
  • Clinical Review (124)
  • COVID-19 (15)
  • Dementia (7)
  • Epilepsy (9)
  • Headache (4)
  • History (29)
  • Movement Disorders (3)
  • Multiple Sclerosis (16)
  • Neurological Literature (3)
  • Neurological Signs (2)
  • Neurosurgery (18)
  • Nutrition (5)
  • Pain (3)
  • Parkinson's Disease (28)
  • Personal Perspectives (2)
  • Rehabilitation (35)
  • Sleep (14)
  • Special Feature (45)
  • Stroke (11)
  • Supplements (1)

Nutrition and Stem Cells as Emerging Therapies for Neurodegenerative Disease

Neurodegenerative disease represents an ever-increasing burden to the UK, measured both in decrease in the length and quality of life for patients, and in rising economic cost to the NHS and social care. For example, the prevalence of Parkinson’s disease (PD) in the UK is predicted to almost double between 2018 and 2065, from approximately 145,000 to over 256,000 cases. Like PD, dementia (including Alzheimer’s disease), Huntington’s disease (HD), multiple sclerosis (MS) and other neurodegenerative disorders continue to challenge researchers and clinicians alike; with little in the way of curative therapies in the pipeline.

Research into the treatment of neurodegenerative disorders is currently focusing on key areas: prevention of onset, neuroprotection, delaying or halting disease progression, and cell replacement. The role of nutrition, both during neural development and throughout life, is now being widely investigated; and nutritional supplementation is being evaluated as a neuroprotective therapy. With the discovery of stem cells, cell replacement therapies are now more widely considered to be a realistic option for patients with specific neurodegenerative diseases.

comorbidities of epilepsy

Nutrition

Essential nutrients, and in particular vitamins, have been linked widely with neurodegenerative disease. For example, it is well established that levels of vitamin D decline in older individuals and are generally lower in populations living in northern latitudes. Vitamin D deficiency has been linked with multiple sclerosis and more recently PD, and this vitamin is currently being tested as a neuroprotective therapy in clinical trials for MS.

Conversely excess nutrients might also be damaging to the central nervous system and there are emerging theories that modern diets may expose neurons to toxic levels of metabolites. Nicotinamide is one such compound. Found in large quantities in red meat, nicotinamide is a precursor to NAD+ the metabolite integral to the production of energy (ATP) within mitochondria. NAD+ levels need to be tightly regulated for normal cellular function, and mitochondrial dysfunction is a key hallmark in multiple neurodegenerative diseases.

There is a plethora of evidence that nutrients and vitamins play a critical role in neural development. For example: retinoic acid (vitamin A), ascorbic acid (vitamin C) and nicotinamide can all influence the conversion of stem cells to neural cells and subsequently neurons.

Thus, there is a clear need to balance nutrient levels both in the developing brain and throughout life. Working at the subcellular level, essential nutrients influence energy supply to neurons, mitochondrial function, and many other cellular processes. There is evidence to suggest that these nutrients may also act on non-neuronal cells within the CNS, including astroglia and immunomodulatory microglia. Therefore, adapting the nutritional balance of those suffering from a neurodegenerative disease may provide a simple yet effective therapy, potentially to slow disease progression or enhance quality of life.

Stem cells and cell replacement therapies

More than four decades of research has been conducted on identifying a suitable cell source for replacement therapies for neurodegenerative disorders, particularly for PD and HD. Indeed, founding editor of ACNR, Professor Roger Barker, currently leads an EU consortium conducting clinical trials in foetal tissue transplants for PD.

Since the early 1990s stem cells have been proposed as a sustainable, reliable and safe source for neuronal replacement. Following extensive laboratory research across the globe, this work is reaching a critical juncture with the launch of two clinical trials involving transplantation of neural progenitors derived from human pluripotent stem cells: at Kyoto University, Japan; and through the New York Stem Cell Consortia, USA.

Key to success in converting stem cells to functional mature neurons that could be used for cell replacement is the recreation of an optimal environment for stem cell differentiation in the laboratory, i.e. mimicking the developing brain in the culture dish.

This creates the unique opportunity to merge nutritional neuroscience and stem cell technology.

The “nutrition and stem cells” series for ACNR will explore key issues and latest research into nutritional neuroscience and stem cells, as emerging therapies for neurodegenerative disease. Focus will be on current research, including: nicotinamide, vitamin D and other essential nutrients; their roles in neuronal development, stem cell differentiation, immune modulation, neuroprotection and potential for clinical application.

The series will also feature updates from ongoing clinical trials using stem cell transplants and will explore the future of this emerging therapy for neurodegenerative disease.

Read the first article in the series Pellagra: 4 D’s and 8 Points by Adrian Williams.

Image credit: Unsplash User Brooke Lark

Related

Tags: ACE2, ageing, Covid-19, fNicotinamide, Meat transitions, tuberculosis

  • Published by Whitehouse Publishing
  • The Lynch, Mere, Wiltshire BA12 6DQ, United Kingdom
  • info@acnr.co.uk
  • +44 1747 860168

FOLLOW US

  • Facebook
  • Instagram
  • Twitter
  • Linkedin

ACNR SIGNUPS

Join our email list to be notified when there is new content or upcoming events. For UK-based specialists join our mailing list for the journal.

© 2022 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.

SIGN UP FOR OUR EMAILING LIST

Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.

For UK-based specialists, sign up for our journal mailing list.